Post Marketing Surveillance in Japan on Long Term Drug Use of JARDIANCE Tablets in Patients With Type 2 Diabetes Mellitus
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 22 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 21 Feb 2017 Planned number of patients changed from 6000 to 8000.
- 07 Jul 2015 New trial record